Neurizon Therapeutics (NUZ.AX) Earnings Analysis
Neurizon Therapeutics (NUZ.AX) has no confirmed upcoming earnings date. Trailing P/E -1.66.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does NUZ.AX next report earnings?
No confirmed upcoming earnings date is currently scheduled for NUZ.AX. This page updates as the calendar is published.
NUZ.AX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2024-08-30 | -0.0164 AUD | n/a | n/a | n/a |
NUZ.AX valuation and analyst view
| Trailing P/E | -1.66 |
|---|---|
| Trailing EPS | -0.03729 AUD |
| Price / book | 9.78 |
| Dividend yield | 0.00% |
| Market cap | 0.05B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Neurizon Therapeutics (NUZ.AX)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for NUZ.AX. This page updates as the calendar is published.
Did NUZ.AX beat earnings last quarter?
Consensus estimate data was not available for NUZ.AX's 2024-08-30 report.
What is NUZ.AX's current P/E ratio and EPS?
NUZ.AX trades at a trailing P/E of -1.66 on trailing EPS of -0.03728701636976028 AUD.
What do analysts rate NUZ.AX?
NUZ.AX has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.